# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Peter Lawson maintains Macrogenics (NASDAQ:MGNX) with a Overweight and lowers the price target from $25 to ...
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.
Editor’s note: This story has been updated to correct an error in the price action of Charter Communications stock.
JMP Securities analyst Silvan Tuerkcan maintains Macrogenics (NASDAQ:MGNX) with a Market Outperform and lowers the price tar...
BMO Capital analyst Etzer Darout downgrades Macrogenics (NASDAQ:MGNX) from Outperform to Market Perform and lowers the price...